PolyPid Ltd. Market Cap 2011-2026 | PYPD

As of March 17, 2026 PolyPid Ltd. has a market cap of $ 74.1 M

Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.^[1]

Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.

This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.

Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.

Annual Market Cap PolyPid Ltd.

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
67.7 M	18.7 M	7.65 M	227 K	2.52 M	107 M	2.25 M	196 K	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
107 M	196 K	25.8 M

References

Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.

Market Cap of other stocks in the Biotechnology industry

Issuer	Market Cap	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	315 M	-	2.43 %	$ 254 M	Germany
AbCellera Biologics ABCL	962 M	$ 3.55	-0.42 %	$ 1.06 B	Canada
Acorda Therapeutics ACOR	16.7 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	40.7 M	-	4.01 %	$ 150 M	Canada
Advaxis ADXS	1.87 M	-	-9.65 %	$ 45.9 M	USA
AC Immune SA ACIU	305 M	$ 3.24	3.35 %	$ 229 M	Schweiz
I-Mab IMAB	127 M	-	-	$ 866 M	China
Aeglea BioTherapeutics AGLE	724 M	-	-	$ 1.01 B	USA
AgeX Therapeutics AGE	14.1 K	-	-10.17 %	$ 12.2 K	USA
Alexion Pharmaceuticals, Inc. ALXN	33.6 B	-	-	$ 40.3 B	USA
Biophytis SA BPTS	549 M	-	-13.47 %	$ 169 M	France
Albireo Pharma ALBO	538 M	-	-0.23 %	$ 916 M	USA
Aileron Therapeutics ALRN	38.2 M	-	10.36 %	$ 9.8 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	28.9 M	-	-1.52 %	$ 24.7 M	USA
ADC Therapeutics SA ADCT	1.22 B	$ 4.14	-1.9 %	$ 105 M	Schweiz
Midatech Pharma plc MTP	79 M	-	-18.52 %	$ 27.3 M	Britain
Aptorum Group Limited APM	4.09 M	$ 0.82	4.22 %	$ 4.47 M	China
argenx SE ARGX	13.8 B	$ 714.55	1.6 %	$ 25 B	Niderland
Adverum Biotechnologies ADVM	76.4 M	-	-	$ 86.2 M	USA
Ascendis Pharma A/S ASND	7.37 B	$ 231.26	0.1 %	$ 5 B	Danmark
Alterity Therapeutics Limited ATHE	895 M	$ 3.4	-5.82 %	$ 8.18 B	Australia
Atea Pharmaceuticals AVIR	426 M	$ 6.09	0.66 %	$ 496 M	USA
Applied Genetic Technologies Corporation AGTC	32.8 M	-	-	$ 26.5 M	USA
Applied Molecular Transport AMTI	22.1 M	-	-	$ 10.1 M	USA
Arcturus Therapeutics Holdings ARCT	217 M	$ 6.6	-0.45 %	$ 181 M	Israel
Институт стволовых клеток человека ISKJ	2.83 B	-	-	-	Russia
BioCardia BCDA	8.9 M	$ 1.37	7.87 %	$ 29 M	USA
Akero Therapeutics AKRO	3.25 B	-	-	$ 3.67 B	USA
Athersys ATHX	364 M	-	3.77 %	$ 22.4 M	USA
Akouos AKUS	172 M	-	0.23 %	$ 488 M	USA
Acer Therapeutics ACER	12.1 M	-	2.71 %	$ 14 M	USA
ARCA biopharma ABIO	484 M	-	1052.0 %	$ 415 M	USA
Allena Pharmaceuticals ALNA	71.4 M	-	3.16 %	$ 1.9 M	USA
Aeterna Zentaris AEZS	41.4 M	-	5.93 %	$ 314 M	Canada
AlloVir ALVR	49 M	-	4.14 %	$ 49.1 M	USA
Catalyst Biosciences CBIO	999 M	$ 11.29	-2.5 %	$ 1.01 B	USA
Anika Therapeutics ANIK	373 M	$ 14.61	1.71 %	$ 214 M	USA
Aptinyx APTX	9.48 M	-	-39.0 %	$ 4.57 M	USA
Aptose Biosciences APTO	2.32 M	-	-45.71 %	$ 1.2 M	Canada
AVEO Pharmaceuticals AVEO	98 M	-	-	$ 521 M	USA
Ayala Pharmaceuticals AYLA	7.72 M	-	-	$ 7.46 M	Israel
BioNTech SE BNTX	62.9 B	$ 92.9	2.61 %	$ 27.2 B	Germany
Aytu BioScience AYTU	15.8 M	$ 2.64	-	$ 16.6 M	USA
CNS Pharmaceuticals CNSP	520 K	$ 2.36	-3.67 %	$ 902 K	USA
CorMedix CRMD	456 K	$ 6.57	0.46 %	$ 473 K	USA
Avenue Therapeutics ATXI	544 K	-	-52.27 %	$ 4.45 M	USA
Burford Capital Limited BUR	2.09 B	$ 8.24	2.36 %	$ 1.33 B	Britain
Autolus Therapeutics plc AUTL	424 M	$ 1.5	-0.99 %	$ 383 M	Britain
Athira Pharma ATHA	16.2 M	-	-	$ 269 M	USA
CureVac N.V. CVAC	3.53 B	-	-	$ 867 M	Germany